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Human physiology differs significantly between females and males. In particular, the 2 sexes vary in regulating 
thrombosis, coagulation, and fibrinolysis.1–8 Endogenous 
estrogen influences the activity of plasminogen activa-
tor inhibitor-1, the key player in fibrinolytic activity in both 
healthy5 and pathological conditions.6–8 It is unknown whether 
females respond differently to pharmacological agents that 
interact with coagulation and fibrinolysis.
Few stroke studies have investigated any sex-related effect 
on intravenous recombinant tissue-type plasminogen activator 
(r-tPA) in comparison to untreated controls.9–11 An analysis of 
5 clinical trials in acute ischemic stroke found that females 
experience a greater treatment effect, measured by differential 
attainment of modified Rankin Scale (mRS) score of 0 to 1 
versus placebo and compared with males at 90 days.9 In con-
trast, pooling those data with all other randomized controlled 
trial data presently available in an individual patient data meta-
analysis, no sex-by-r-tPA treatment interaction was evident (P 
for heterogeneity <3 hours=0.95 and 3–4.5 hours=0.53).11
As for the natural course of an acute ischemic stroke, 
surprisingly few studies investigated outcome differences 
between the sexes. Among those, a minority used the widely 
accepted mRS at day 90 or later as outcome measure12–18 
emphasizing the need for data on functional outcome on this 
scale analyzed by sex. However, several aspects should be 
considered because they may lead to sex-specific differences 
in observational studies and clinical trials.
Some important risk factors in stroke are more prevalent in 
females than males—for example, diabetes mellitus,19,20 atrial 
fibrillation,21–23 and arterial hypertension.24 All of these are 
known to influence the pathophysiology and functional out-
come of stroke.25 In addition, age-dependent and life-phase–
dependent stroke risk for females differs considerably from 
males.26 Below the age of 85 years, ischemic stroke strikes 
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fewer females than males, but this tendency is reversed at 
higher age.27–29 Specific hormonal states (eg, postmeno-
pausal30,31) also lead to elevated stroke risk in females. Age—a 
proven risk factor for stroke—is the best surrogate marker to 
take into account these risk differences because they are likely 
to impact outcome; nonconsideration might lead to bias.
We aimed to investigate sex-specific differences in post-
stroke outcome in individual patient-level data pooled from 
randomized controlled trials. Using novel matching tech-
niques, we approximated a randomized experiment account-
ing for covariates that differ between sexes. We evaluated 
2 hypotheses allowing for potential effects in different age 
groups to emerge. First, we investigated whether the natural 
course of stroke is different between males and females with-
out r-tPA treatment, after adjustment for relevant prognostic 
factors. Second, using a similar adjustment for relevant prog-
nostic factors, we investigated whether the response to r-tPA 
was different between males and females.
Methods
Data Source and Selection
Data were extracted from the VISTA (Virtual International Stroke 
Trials Archive). We collected demographics, clinical data, and out-
come measures from trials in acute ischemic stroke conducted from 
1998 to 2008. Within these, many patients had received intravenous 
thrombolysis as standard of care.32 Our analysis did not require new 
ethical approval. Trials that are pooled within VISTA follow the 
Declaration of Helsinki and were approved by local authorities.
Preprocessing
To achieve multivariate balance in the distribution of covariates 
between the 2 sexes (female and male) and to simulate a randomized 
trial, coarsened exact matching was performed independent of out-
come. Importantly, unobserved variables are not accounted for, which 
clearly differentiate this method from a prospective randomization 
process. Coarsened exact matching differs conceptually from other 
matching methods such as propensity score matching.33,34 Coarsened 
exact matching aims at reducing the degree of model dependence. 
It also attempts to reduce bias in the estimation of the outcome.35 
The method has been described in detail elsewhere,33,34 but a short 
summary can be found in the Methods in the online-only Data 
Supplement.
Variable Selection
We based our variable selection for the matching process on sex-spe-
cific and general pathophysiological considerations of acute ischemic 
stroke. We used age,26,36 baseline National Institutes of Health Stroke 
Scale (NIHSS),22 hemisphere indicating the localization of the stroke 
lesion,37 and history of diabetes mellitus,19,20,38 atrial fibrillation,22,23 
myocardial infarction,39 and hypertension.40 Age and baseline NIHSS 
strata were determined based on equality of frequencies in each stra-
tum. We analyzed patients with a time from onset of stroke symptoms 
to randomization of <7 hours.
Statistical Analysis
Continuous variables are described as median and interquartile 
range, and categorical variables as count and percentages. For uni-
variate group comparisons, the Student t Test, the Mann–Whitney U 
Test, or the Fisher exact test was used as appropriate.
The primary outcome measure was the mRS at 90 days analyzed 
using ordinal logistic regression.41 Dichotomized outcomes (mRS 
score of 0–1 for favorable outcome and mRS score of 0–2 for good 
outcome) were considered secondary outcomes and calculated by 
logistic regression analysis. Model fits were examined by inspect-
ing residual plots, calibration measures (Akaike information crite-
rion), and the Hosmer and Lemeshow goodness of fit test. We report 
common odds ratios (OR) and 95% confidence intervals (CI). The 
number needed to treat (NNT) was calculated by the adjusted risk 
difference method.42 For survival analysis, a cox proportional hazard 
model was estimated. We report hazard ratio (HR) and 95% CIs in 
addition to the visualized Kaplan–Meier estimate. About bleeding 
complications, the following definitions were analyzed: (1) any hem-
orrhage, (2) any serious or fatal hemorrhage, (3) symptomatic intra-
cranial hemorrhage after NINDS (National Institute of Neurological 
Disorders and Stroke) and ECASS (European Cooperative Acute 
Stroke Study)-II definition (for more details please visit the online-
only Data Supplement).
For nonlinearity of most influential variables of age and NIHSS, 
restricted cubic splines were used if the model including splines 
showed benefit over the old model by means of a likelihood ratio 
test. We allowed for additive (4 factor variable,43 relative excess risk 
because of interaction [RERI]44) and multiplicative interactions (like-
lihood ratio test) between sex and r-tPA status and between age and 
sex. RERI is a metric of additivity of effects on a relative risk scale 
indicating the public health importance of interactions. RERI 95% CIs 
that cross zero indicate nonsignificance of additive interaction effects.
We present the matched analysis in the main part of the article, 
and the unmatched and sensitivity analysis in the online-only Data 
Supplement of the article. For sensitivity analysis, we investigated 
subgroups that are known to differ between sexes, namely atrial fibril-
lation and diabetes mellitus. VISTA includes data from the Glycine 
Antagonist in Neuroprotection trials,45,46 which excluded patients 
with early neurological recovery. Acknowledging this as a possible 
source of bias, we also reran the analysis excluding those data.
Statistical analysis was performed using R47–49 and the statistical 
package for the social sciences (IBM Corp. Released 2012. IBM 
SPSS Statistics for Windows, Version 21.0; IBM Corp, Armonk, NY).
Figure 1. Study flow chart. r-tPA indicates recombinant tissue-
type plasminogen activator; and VISTA, Virtual International 
Stroke Trials Archive.
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A study flow chart gives the reader an overview of the study work 
flow of data selection of complete cases, quasirandomization, and 
analysis (Figure 1; detailed methods of statistical analysis are avail-
able in the online-only Data Supplement).
Results
The complete cases data set contained 8028 patients (Figure 1), 
2403 (29.9%) of whom received intravenous thrombolysis 
treatment (r-tPA). After preprocessing, the matched cohort 
comprised 4575 patients with 2204 (48.2%) females and 
equal proportion of thrombolyzed patients among females and 
males (24.2% r-tPA, respectively).
Age distribution (median 70 years; interquartile range 60–
78) between the sexes was characteristically shifted as seen in 
population-based samples, with more younger males between 
the age of 45 and 70 years and more older females between 
the age of 75 and 95 years (Figure I in the online-only Data 
Supplement). Matched subjects showed substantial improve-
ment in age distribution overlap (Figure I in the online-only 
Data Supplement). Median NIHSS score was 12 (interquartile 
range 8–17) in the whole cohort and 11 (interquartile range 
8–16) in the matched cohort. Baseline characteristics by groups 
of sex before and after matching are presented (Table 1).
The outcome distribution of mRS at day 90 for the entire 
cohort (Figure 2A) and for the matched cohort (Table 2) with 
strata of sex and r-tPA status is shown.
Females and Males Without r-tPA (Natural Course)
In patients who did not receive intravenous thrombolysis 
(n=3504), ordinal analysis of mRS adjusting for stroke- and 
sex-related prognostic factors (age, NIHSS, onset of stroke 
to time of randomization, body mass index, and risk factors 
[hypertension, diabetes mellitus, smoking, atrial fibrillation, 
and myocardial infarction]) suggested comparable results 
for females (n=1707) versus males (n=1797; OR, 0.93; 95% 
CI, 0.83–1.06). Dichotomized measures were also com-
parable between the sexes (favorable outcome: OR, 1.03; 
95% CI, 0.88–1.22 and good outcome: OR, 0.93; 95% CI, 
0.79–1.09).
Effect Measure of r-tPA by Sex
Ordinal Measure
Cochran–Mantel–Haenszel P value for the crude analysis 
(P=0.0268) suggested a sex-specific difference in favor of 
males in the response to r-tPA (OR, 0.895; 95% CI, 0.813–
0.986). However, after preprocessing (matching) and adjust-
ing for confounders of age, NIHSS, onset of stroke to time 
of randomization, body mass index, stroke localization, and 
risk factors (hypertension, diabetes, smoking, atrial fibrilla-
tion, and myocardial infarction) in regression analysis, no 
significant effect modification of sex on r-tPA was found 
(P
Interaction
=0.46, RERI=0; Table 2; Table I in the online-only 
Data Supplement). Various levels of adjustment did not alter 
this finding (data not shown). Predicted probabilities by each 
response category of the mRS for treatment groups within sex 
strata are shown (Figure 2B).
Favorable and Good Functional Stroke Outcome
The adjusted NNT for 1 female to achieve favorable and 
good functional outcome at 90 days after stroke were 
11.2 and 6.8, respectively; these were similar to the NNTs 
for males (Table 2). Consequently, no significant sex-
by-r-tPA interaction was found—neither for favorable 
(P
Interaction
=0.185, RERI=−0.06) nor for good functional out-
come (P
Interaction
=0.792, RERI=−0.13; Table 2).
Mortality Within 90 Days After Stroke
In the matched cox regression, mortality in females was 
significantly lower than in males (female: HR, 0.82; 95% 
CI, 0.71–0.95; Figure 3). Adjusting for r-tPA (HR, 0.88; 
95% CI, 0.74–1.05), age (HR, 1.05; 95% CI, 1.04–1.06), 
and baseline NIHSS (HR, 1.13; 95% CI, 1.12–1.14) did not 
noticeably change the influence of sex (female: HR, 0.81; 
95% CI, 0.7–0.94). Further adjustment with all risk factors 




Female, n=3630 Male, n=4398 P Value Female, n=2204 Male, n=2371 P Value
Covariates, median (interquartile range)
  Age, y 74 (65–80) 70 (60–77) <0.001 70 (59–77) 70 (59–77) 0.696
  Onset to time of randomization, h 4 (3.4–5) 4 (3.3–5) 0.044 4.1 (3.4–5) 4 (3.3–5.1) 0.676
  Stroke severity at baseline, NIHSS 13 (8–18) 12 (8–17) <0.001 11 (8–16) 11 (8–16) 0.874
  Body mass index 26.1 (23.3–29.4) 26.1 (24–29.1) 0.757 26.4 (23.4–29.6) 26.1 (24–29) 0.276
Risk factors, n (%)
  History of hypertension 2772 (76.4) 2980 (67.8) <0.001 1672 (75.9) 1799 (75.9) >0.999
  History of diabetes mellitus 815 (22.5) 1027 (23.4) 0.354 323 (14.7) 347 (14.6) >0.999
  History of atrial fibrillation 1149 (31.7) 1038 (23.6) <0.001 414 (18.8) 445 (18.8) >0.999
  History of myocardial infarction 395 (10.9) 818 (18.6) <0.001 113 (5.1) 122 (5.1) >0.999
Treatment status, n (%)
  Recombinant tissue-type plasminogen 
activator
1035 (28.5) 1368 (31.1) 0.012 534 (24.2) 574 (24.2) >0.999
NIHSS indicates National Institutes of Health stroke scale.
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did not change the OR (data not shown). We observed no 





Overall, we found no evidence of a sex-by-r-tPA interaction 
when analyzing any hemorrhage, any serious or fatal hemor-
rhage, and symptomatic intracranial hemorrhage following 
definitions of NINDS and ECASS-II (all P>0.05).
Risk Modification of Age-by-Sex
Estimating good outcome as a function of age using splines 
with 4 df showed significant interaction with sex (Figure 4; 
age P
Interaction
=0.0042, RERI=−7.8 [95% bias corrected and 
accelerated (BCa) CI −44.5, −0.66]; age′ P
Interaction
=0.0009, 
RERI=−1.5 [95% BCa CI −9.58, −0.02]; and age″ 
P
Interaction
=0.0018, RERI=4.07 [95% BCa CI −0.812, 36.415]). 
Other outcome definitions showed no effect modification of 
such kind.
Discussion
Our sex-balanced analysis suggests similar outcomes between 
the sexes in their natural course of the disease as measured by 
mRS at day 90 after surviving a stroke. We provide evidence 
from independent clinical trial data that females respond to 
recombinant intravenous plasminogen activator similarly to 
males. Furthermore, we demonstrate relevant outcome varia-
tion of age-by-sex emphasizing improved outcome estimates 
when considering age in a nonlinear manner.
Sex-Specific Natural Course as 
Measured by mRS at Day 90
In the pooled analysis of 5 randomized controlled ischemic 
stroke trials,9 the female control group fared worse than the 
male control group. Females were under-represented, because 
of recruitment rates below 43 and as low as 32%. This may be 
explained by a higher threshold for treating younger females 
with child-bearing potential, (including the exclusion of these 
females unless they were on reliable contraception) or by a 
lower event rate of ischemic stroke in females below the age 
of 85.27,29 However, this imbalance weights the analysis of trial 
data in favor of males.
We reviewed 7 observational studies that reported sex dif-
ferences using mRS at day 90 or later (for a detailed overview 
see Table II in the online-only Data Supplement). Investigating 
predominantly mild strokes, moderate-to-severe strokes were 
under-represented in those studies.12–18 Two study cohorts that 
featured a slightly higher median baseline NIHSS (617 and 
9.413) reported equipoise between the sexes in functional out-
come when adjusting for age and stroke severity. Earlier work 
investigated sex difference in functional outcome measuring 
Stroke Impact Scale-16,50 general dependency,51 physical dis-
ability using modified Katz activities of daily living,29 quality 
of life measures,52 or the Barthel Index.53 However, these mea-
sures may not be directly comparable to the mRS at day 90 or 
180 after stroke.54
To this body of knowledge, our present study adds a less 
biased view, being from balanced sex cohorts including a 
representative stroke severity range and analyzed by means 
of mRS at day 90. Females and males in ordinal and dichoto-
mized outcomes (excellent outcome mRS score of 0–1 and 
good outcome mRS score of 0–2) yielded similar estimates. 
Effect modification of age-by-sex gives us insights into 
how various female cohorts might represent different out-
come risks—showing favor or disfavor when compared with 
males.
As for mortality, our study complements previously pub-
lished data.51,55 For example, results from the Centers for Disease 
Figure 2. Outcome distributions of 7-point scale 
of the modified Rankin Scale for females (red) 
and males (blue) in their respective treatment 
status are given; (A) numbers are absolute num-
bers of the entire cohort (not matched, n=8028). 
B, Numbers are predicted probabilities from the 
full proportional odds model of the matched 
cohort (n=4575). r-tPA indicates recombinant 
tissue-type plasminogen activator.
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Control and Prevention WONDER (Wide-ranging Online Data 
for Epidemiological Research) database highlighted that mid-
dle-aged women died less often than men, whereas this finding 
was reversed in women older than 85.55 In our study, the median 
age of women was 70 (interquartile range 59–77), and mortal-
ity was significantly lower in women than men supporting the 
hypothesis of a mean survival benefit in middle-aged women. 
Noteworthy, our study is the first to report on highly balanced 
mortality data that take account of differences in age, stroke 
severity, and sex-specific risk factors for stroke.
Sex-Specific Response to r-tPA
Our results are in line with the results provided by Emberson 
et al11 in the individual patients data meta-analysis reporting 
no sex-by-r-tPA-treatment interaction in good stroke outcome 
(mRS score of 0–1, P for heterogeneity <3 hours=0.95 and 
3–4.5 hours=0.53). An earlier analysis of 5 randomized con-
trolled ischemic stroke trials9 had found females who received 
r-tPA to achieve equal outcomes (as defined by mRS score of 
0–1) when compared with males who received r-tPA. Because 
the female control group fared worse in their analysis, the 
authors inferred that women benefited more than men from 
intravenous r-tPA treatment. However, in our study, we were 
not able to reject the null hypothesis of a common treatment 
effect of r-tPA between the sexes.
Our study has several strengths. Estimates derived from 
this sex-balanced cohort compare well with results from 
the pooled analysis.56 Although matching lowered the 
Table 2. Outcome Measured Using mRS at Day 90 After Stroke in Control Patients and Patients Who Received r-tPA
Outcome 
Category Sex r-tPA
No. of Matched Patients mRS Category Outcome Measures Interaction


















 Male No 229 353 247 253 306 104 305 1 (Referent) … …   
 
Male Yes 82 117 85 77 95 25 93
0.61  
(0.51 to 0.73)
… …   
 
Female No 194 287 195 239 344 151 297
0.93  
(0.82 to 1.05)
… …   
 
Female Yes 62 86 69 76 96 29 79
0.63  
(0.53 to 0.75)
… …   
mRS score 
of 0–1












Male Yes 199  375     
1.73  
(1.37 to 2.20)
    
 









Female Yes 148  349     
1.45  
(1.13 to 1.86)
    
mRS score 
of 0–2












Male Yes 284   290    
1.76  
(1.39 to 2.23)
    
 









Female Yes 217   280    
1.45  
(1.12 to 1.88)
    
Analyzed are groups of sex (female and male) demonstrating absent effect modification of r-tPA by sex: adjusted for age, baseline National Institutes of Health Stroke 
Scale, localization of stroke, history of diabetes mellitus, history of atrial fibrillation, history of arterial hypertension, history of myocardial infarction, history of smoking, 
body mass index, and time from symptom onset to randomization. CI indicates confidence interval; mRS, modified Rankin Scale; and r-tPA, recombinant tissue-type 
plasminogen activator.
*Measures of interaction on additive scale: relative excess risk because of interaction (RERI)—a value of zero means no interaction.
†Measures of interaction on multiplicative scale: likelihood ratio test.
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mean age (68.7±12.9 versus 71±13), stroke severity (12±7 
versus 12.7±5.7) and the NNT were largely unchanged 
(adjusted NNT for mRS score of 0–1: 11 versus NNT 12.6 
in the pooled analysis). Our study features sex-specific out-
come results measured by mRS at day 90 after the natural 
course of ischemic stroke disease in a well-balanced cohort 
adjusted for known prognostic sex-specific and general fac-
tors of stroke. Furthermore, it is the first study to evaluate the 
sex-specific response to r-tPA treatment in an independent, 
balanced trial cohort. Demonstrating age-by-sex interaction 
in outcome estimation, it offers valuable insight into how 
heterogeneous cohorts can be depending on a sex-specific 
age distribution.
Our study has limitations. The study sample is not popula-
tion based, rather it was derived from clinical trial cohorts. 
However, the study sample shows a typical sex-specific age 
distribution as seen in population samples.29 The NIHSS dis-
tribution is linked to the selection process in trials, which on 
the other hand improves comparability to the same. Results 
should not be generalized before they have been replicated in 
a population-based sample. No pregnant women were in the 
trials that are pooled within VISTA—therefore, these results 
are not generalizable to pregnant women, and there are age-
specific changes in selection among females that do not apply 
to males. In this study, we did not have information about hor-
monal status of VISTA trial patients. Thus, the study was not 
intended to investigate for patients who were taking hormone 
replacement therapy. This may be a potential bias because 
female stroke patients receiving hormone replacement therapy 
are at increased risk for stroke.57
We sought to remove bias and adjust for potential con-
founders. Nevertheless, this study is retrospective. Sources 
of bias may be the unknown number of patients experiencing 
posterior circulation stroke, the selection of complete cases, 
and the selection of matching parameters. We did not adjust 
for potential confounders of admission blood pressure and 
stroke subtype. Our selection was based on pathophysiologi-
cal considerations of stroke in general and especially depend-
ing on sex in variables that are well-established confounders 
in stroke outcome estimation.
Figure 4. Upper, Probability of reaching good outcome (modified 
Rankin Scale [mRS] score of 0–2) as a function of age-by-sex 
strata in the matched cohort. Lower, Corresponding delta values.
Figure 3. Kaplan–Meier estimates by 
groups of sex within treatment strata 
in matched cohort. (Vertical scale was 
adjusted for visualization and does not 
extend to zero.) CI indicates confidence 
interval; HR, hazard ratio; and r-tPA, 
recombinant tissue-type plasminogen 
activator.
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Conclusions
This study considered sex-specific age and risk factor issues, 
optimized for comparability between sex cohorts, and com-
pares well to the cohort of the pooled analysis of ischemic 
stroke trials.
Females in our control group had similar outcomes to males 
of the control group. As for the sex-specific response to r-tPA, 
we could not reject the null hypothesis of a common treatment 
effect of r-tPA between the sexes. We could not find evidence 
for a meaningful relationship between sex, r-tPA, and bleed-
ing complications. Finally, we found that consideration of a 
nonlinear sex-by-age interaction significantly improved esti-
mates of outcome—this may be important to be considered in 
future analyses of sex of data on stroke patients.
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